Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

ABCS abstract #S3-7; December 8, 9:30 – 11:15AM).
  • Zometa ABCSG-12 (Austrian Breast & Colorectal Cancer Study Group Trial) long-term data will examine possible carry-over anticancer benefits of zoledronic acid three years after treatment completion in premenopausal women with endocrine-responsive early breast cancer receiving adjuvant goserelin and endocrine therapy (SABCS abstract #S1-2; December 7, 9:15 – 11:30AM) and five-year ZO-FAST (ZOmeta-Femara Adjuvant Synergy Trial) follow-up data on long-term overall survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant zoledronic acid and letrozole (SABCS abstract #S1-3; December 7, 9:15 – 11:30AM).
  • BKM120 – Two studies investigating the activity of BKM120, a pan-PI3K inhibitor, in advanced breast cancer: data from a trial evaluating the safety profile and clinical activity of BKM120 as a single agent for the treatment of patients with metastatic breast cancer (SABCS abstract  #P3−16−01; December 8, 5:00 – 7:00PM) and data from a Phase I/II study evaluating BKM120 in combination with trastuzumab in patients with HER2 overexpressing metastatic breast cancer resistant to trastuzumab-containing therapy (SABCS abstract #PD09−03; December 9, 5:00 – 7:00PM).
  • Highlights at ASH include:

  • Tasigna – ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) 36-month update of the ENESTnd study comparing Tasigna to Gleevec® (imatinib mesylate) tablets(**) in patients with newly diagnosed chronic phase Ph+ chronic myeloid leukemia (ASH abstract #452; December 12, 10:30AM – 12:00PM) and results from ENESTcmr trial assessing the efficacy and safety of switching patients with residual molecular disease on Gleevec treatment to Tasigna (ASH abstract #606; December 12, 2:45 – 4:15PM).
  • Exjade &#
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related biology technology :

    1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
    2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
    3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
    4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
    5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
    6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
    7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
    8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
    9. Novartis Class Awarded $250 Million in Punitive Damages
    10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
    11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... Alan Turing, the British mathematician (1912-1954), is famous for ... the 20th century. In 1936 he published a paper, ... first formal concept of a computer algorithm. He next ... designing the machines which cracked the German military codes, ... crucial battles. And in the late 1940,s he turned ...
    (Date:7/31/2014)... 2014 The SNIS Foundation recognized its ... fund a translational research project.  The first award ... was presented at the Society of NeuroInterventional Surgery ... Colorado Springs, CO. ... neurovascular conditions, SNIS formed the SNIS Foundation, in ...
    (Date:7/31/2014)... July 31, 2014 North Shore Towers, a ... partnered with GI Energy, one of the nation’s leading combined ... million upgrade of its 43-year-old CHP system. The original CHP ... an effort to extend the life of the plant, GI ... associated electrical and heat recovery equipment, while maintaining continuous operation ...
    (Date:7/31/2014)... Senomyx , Inc. (NASDAQ: ... taste science technologies to discover, develop, and commercialize ... ingredient supply industries, today reported financial results for ... second quarter with $33.6 million in cash and ... past quarter Senomyx achieved another important milestone with ...
    Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
    ... 9, 2011 Anticipating a catastrophic increase in Alzheimer,s ... much-anticipated California State Plan for Alzheimer,s disease, a disease ...  The plan is a 10-year course of action with ... this growing health crisis.   Alzheimer,s will ...
    ... CHICAGO, March 9, 2011 GlobalCare Clinical Trials, ... America. GlobalCare provides selected clinical study visits at ... or alternate settings – for study patients to ... therapeutic areas, genomics and personalized medicine in all ...
    ... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... OC Growth Stock Conference on Tuesday, March 15, 2011, at ... the Ritz Carlton Laguna Niguel in Dana Point, CA. ... of Palatin Technologies, will provide an update on Palatin,s corporate ...
    Cached Biology Technology:California Leaders Confront Alarming Rise in Alzheimer's Cases 2California Leaders Confront Alarming Rise in Alzheimer's Cases 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4
    (Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
    (Date:7/31/2014)... models against the highly infectious and virulent bacterium, ... kills approximately 30,000 Americans annually. The research is published ... , In the study, the vaccine protected the ... by C. difficile , as well as from ... the human disease, after only two immunizations. , ...
    (Date:7/31/2014)... identify and treat those with fibromuscular dysplasia (FMD). FMD ... arteries in the body, which can restrict blood flow to ... report appearing in August 2014 issue of The ... may not be limited to the arteries as currently believed. ... and joints, as well as evidence that inflammation may be ...
    Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
    ... Bill Middleton peer into the ancient Mexican past. In ... help build the most accurate and most detailed landscape ... where the Zapotec people formed the first state-level and ... off the street about Mexican archeology, theyll say Aztec, ...
    ... off of the University of Granada Lorgen, in collaboration with ... de las Nieves of Granada, has managed to develop a ... the eighth week of pregnancy separating the DNA found in ... been tested through a clinical trial in 120 pregnant women, ...
    ... ORCH ) today announced that Thomas A. Bologna, ... present at the 2008 Bank of,America Health Care Conference ... p.m. PDT., Mr. Bologna will provide a brief ... A link to the live webcast of Mr.,Bologna,s presentation ...
    Cached Biology News:Archaeologist uses satellite imagery to explore ancient Mexico 2Archaeologist uses satellite imagery to explore ancient Mexico 3A new analysis method allows to find out the sex of the baby from the second month of pregnancy 2